Cargando…

A prognostic model for patients with primary extramedullary multiple myeloma

Background: Extramedullary disease is a manifestation of multiple myeloma, the prognosis of which remains poor even in the era of novel drugs. Therefore, we aimed to develop a predictive model for patients with primary extramedullary multiple myeloma (EMM). Methods: Clinical and laboratory data of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Limei, Chen, Shuzhao, Wang, Weida, Wang, Yun, Liang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732373/
https://www.ncbi.nlm.nih.gov/pubmed/36506092
http://dx.doi.org/10.3389/fcell.2022.1021587
_version_ 1784846117853200384
author Zhang, Limei
Chen, Shuzhao
Wang, Weida
Wang, Yun
Liang, Yang
author_facet Zhang, Limei
Chen, Shuzhao
Wang, Weida
Wang, Yun
Liang, Yang
author_sort Zhang, Limei
collection PubMed
description Background: Extramedullary disease is a manifestation of multiple myeloma, the prognosis of which remains poor even in the era of novel drugs. Therefore, we aimed to develop a predictive model for patients with primary extramedullary multiple myeloma (EMM). Methods: Clinical and laboratory data of patients diagnosed with primary EMM between July 2007 and July 2021 were collected and analyzed. Univariate and least absolute shrinkage and selection operation Cox regression analyses (LASSO) were used to select prognostic factors for overall survival (OS) to establish a nomogram prognostic model. The performance of the model was evaluated using concordance index which was internally validated by bootstraps with 1,000 resample, area under the curve (AUCs), and calibration curves. Results: 217 patients were included in this retrospective study. Patients with EMM had a higher rate of belonging to the male sex, age >50 years, advanced Durie–Salmon stage III, hypercalcemia, and low hemoglobin level. Compared with patients with bone-related extramedullary disease, those with extraosseous-related extramedullary disease had a higher frequency of advanced Durie–Salmon stage III, lower rate of hypercalcemia, and elevated prothrombin time. The OS and progression-free survival (PFS) of patients with bone-related extramedullary disease were significantly higher than those of patients with extraosseous-related extramedullary disease. After the univariate and LASSO analyses, six prognostic factors, including performance status, number of extramedullary involved sites, β2-microglobulin, lactate dehydrogenase, monocyte–lymphocyte ratio, and prothrombin time, were integrated to establish a nomogram. The model showed robust discrimination with a concordance index (C-index) of 0.775 (95% confidence interval [CI], 0.713–0.836), internally validated with the corrected C-index of 0.756, and excellent performance in time-dependent AUCs compared with other staging systems. The AUCs for 1-, 3-, and 5-year OS were 0.814, 0.744, and 0.832, respectively. The calibration curves exhibited good consistency between the observed and nomogram-predicted OS. The 5-year OS of patients in the high-risk group (23.3%; 95% CI, 13.9%–39.3%) was much worse than that in the low-risk group (73.0%; 95% CI, 62.5%–85.4%; p < 0.001). Conclusion: The nomogram predictive model based on six clinical variables showed good prognostic performance and could better predict individual survival in patients with EMM.
format Online
Article
Text
id pubmed-9732373
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97323732022-12-10 A prognostic model for patients with primary extramedullary multiple myeloma Zhang, Limei Chen, Shuzhao Wang, Weida Wang, Yun Liang, Yang Front Cell Dev Biol Cell and Developmental Biology Background: Extramedullary disease is a manifestation of multiple myeloma, the prognosis of which remains poor even in the era of novel drugs. Therefore, we aimed to develop a predictive model for patients with primary extramedullary multiple myeloma (EMM). Methods: Clinical and laboratory data of patients diagnosed with primary EMM between July 2007 and July 2021 were collected and analyzed. Univariate and least absolute shrinkage and selection operation Cox regression analyses (LASSO) were used to select prognostic factors for overall survival (OS) to establish a nomogram prognostic model. The performance of the model was evaluated using concordance index which was internally validated by bootstraps with 1,000 resample, area under the curve (AUCs), and calibration curves. Results: 217 patients were included in this retrospective study. Patients with EMM had a higher rate of belonging to the male sex, age >50 years, advanced Durie–Salmon stage III, hypercalcemia, and low hemoglobin level. Compared with patients with bone-related extramedullary disease, those with extraosseous-related extramedullary disease had a higher frequency of advanced Durie–Salmon stage III, lower rate of hypercalcemia, and elevated prothrombin time. The OS and progression-free survival (PFS) of patients with bone-related extramedullary disease were significantly higher than those of patients with extraosseous-related extramedullary disease. After the univariate and LASSO analyses, six prognostic factors, including performance status, number of extramedullary involved sites, β2-microglobulin, lactate dehydrogenase, monocyte–lymphocyte ratio, and prothrombin time, were integrated to establish a nomogram. The model showed robust discrimination with a concordance index (C-index) of 0.775 (95% confidence interval [CI], 0.713–0.836), internally validated with the corrected C-index of 0.756, and excellent performance in time-dependent AUCs compared with other staging systems. The AUCs for 1-, 3-, and 5-year OS were 0.814, 0.744, and 0.832, respectively. The calibration curves exhibited good consistency between the observed and nomogram-predicted OS. The 5-year OS of patients in the high-risk group (23.3%; 95% CI, 13.9%–39.3%) was much worse than that in the low-risk group (73.0%; 95% CI, 62.5%–85.4%; p < 0.001). Conclusion: The nomogram predictive model based on six clinical variables showed good prognostic performance and could better predict individual survival in patients with EMM. Frontiers Media S.A. 2022-11-25 /pmc/articles/PMC9732373/ /pubmed/36506092 http://dx.doi.org/10.3389/fcell.2022.1021587 Text en Copyright © 2022 Zhang, Chen, Wang, Wang and Liang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Zhang, Limei
Chen, Shuzhao
Wang, Weida
Wang, Yun
Liang, Yang
A prognostic model for patients with primary extramedullary multiple myeloma
title A prognostic model for patients with primary extramedullary multiple myeloma
title_full A prognostic model for patients with primary extramedullary multiple myeloma
title_fullStr A prognostic model for patients with primary extramedullary multiple myeloma
title_full_unstemmed A prognostic model for patients with primary extramedullary multiple myeloma
title_short A prognostic model for patients with primary extramedullary multiple myeloma
title_sort prognostic model for patients with primary extramedullary multiple myeloma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732373/
https://www.ncbi.nlm.nih.gov/pubmed/36506092
http://dx.doi.org/10.3389/fcell.2022.1021587
work_keys_str_mv AT zhanglimei aprognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT chenshuzhao aprognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT wangweida aprognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT wangyun aprognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT liangyang aprognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT zhanglimei prognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT chenshuzhao prognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT wangweida prognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT wangyun prognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma
AT liangyang prognosticmodelforpatientswithprimaryextramedullarymultiplemyeloma